- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John Schorge on Neoadjuvant Chemotherapy Treatment in Advanced Ovarian Cancer
John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses the findings of his study on neoadjuvant chemotherapy treatment of patients with advanced ovarian cancer.
John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses the findings of his study on neoadjuvant chemotherapy treatment of patients with advanced ovarian cancer.
Transcript
What were the findings of your study that investigated the delivery of neoadjuvant chemotherapy to women with advanced ovarian cancer?
One of the conundrums and controversies in the field is people that present with ovarian cancer— two-thirds of the time it's fairly advanced. Whether to start with surgery first or chemotherapy first has been the dilemma.
Historically, people have started with surgery first, and yet over the last decade or so there's been a lot more evidence that starting with chemotherapy— such as neoadjuvant chemotherapy, which means chemo first– seems to work out just as well in the long run in many cases.
Part of our work was looking at that trend and then determining that as an interval operation— which means halfway through the chemotherapy– if you're able to do a minimally invasive operation, like a standard laparoscopy, people have similar outcomes to open surgery, and a lot fewer side effects and a lot less complication risk.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
